[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502254":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":28,"responsibleParty":225,"collaborators":24,"id":227,"slug":228,"hasResults":229,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":229,"sex":234,"minAge":235,"maxAge":24,"enrollmentInfo":236,"targetDuration":24,"studyType":239,"phases":240,"briefSummary":242,"conditions":243,"keywords":24,"overallStatus":31,"whyStopped":24,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},{"fullName":5,"class":6},"Minoryx Therapeutics, S.L.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Leriglitazone","ACTIVE_COMPARATOR","Leriglitazone Treatment",[13],"Drug: Leriglitazone",{"label":15,"type":16,"description":15,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Leriglitazone at a strength of 15 mg\u002Fml. Once-daily dosing at an initial volume of 10 ml",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Placebo will match the study drug visually and by taste",[15],[29,49,60,75,90,105,115,130,145,161,177,193,209],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Stanford University Medical Center","RECRUITING","Palo Alto","California","94304-5978","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-122.14302,37.44188,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":24,"email":48},"Jacinda Sampson","CONTACT","650-723-0993","jacindas@stanford.edu",{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":35,"countryCode":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":24},"Neuro Medicine Hospital \u002F UF Health","WITHDRAWN","Gainesville","Florida","32608",{"type":38,"coordinates":56},[57,58],-82.32483,29.65163,{"lat":58,"lon":57},{"facility":61,"status":31,"city":62,"state":63,"zip":64,"country":35,"countryCode":36,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Kennedy Krieger Institute","Baltimore","Maryland","21205",{"type":38,"coordinates":66},[67,68],-76.61219,39.29038,{"lat":68,"lon":67},[71],{"name":72,"role":46,"phone":73,"phoneExt":24,"email":74},"Eric Mallack","443-923-2750","Mallack@kennedykrieger.org",{"facility":76,"status":31,"city":77,"state":78,"zip":79,"country":35,"countryCode":36,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":38,"coordinates":81},[82,83],-71.05977,42.35843,{"lat":83,"lon":82},[86],{"name":87,"role":46,"phone":88,"phoneExt":24,"email":89},"Reza Seyedsadjadi","617-726-5175","rseyedsadjadi@mgh.harvard.edu",{"facility":91,"status":31,"city":92,"state":93,"zip":94,"country":35,"countryCode":36,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"University of Minnesota","Minneota","Minnesota","55455",{"type":38,"coordinates":96},[97,98],-95.98559,44.55885,{"lat":98,"lon":97},[101],{"name":102,"role":46,"phone":103,"phoneExt":24,"email":104},"Troy Lund","612-625-4185","lundx072@umn.edu",{"facility":106,"status":51,"city":107,"state":108,"zip":109,"country":35,"countryCode":36,"cosmosGeoPoint":110,"geoPoint":114,"contacts":24},"Health University of Utah","Salt Lake City","Utah","84112",{"type":38,"coordinates":111},[112,113],-111.89105,40.76078,{"lat":113,"lon":112},{"facility":116,"status":31,"city":117,"state":24,"zip":24,"country":118,"countryCode":119,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Hospital Austral","Buenos Aires","Argentina","AR",{"type":38,"coordinates":121},[122,123],-58.37723,-34.61315,{"lat":123,"lon":122},[126],{"name":127,"role":46,"phone":128,"phoneExt":24,"email":129},"Hernan Amartino","+542304387458","carolina.acevedo@resolutioncrs.com",{"facility":131,"status":31,"city":132,"state":24,"zip":24,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Federal University of Sao Paulo","São Paulo","Brazil","BR",{"type":38,"coordinates":136},[137,138],-46.63611,-23.5475,{"lat":138,"lon":137},[141],{"name":142,"role":46,"phone":143,"phoneExt":24,"email":144},"Paulo Sgobbi","+55(11)913323742","pvsgobbi@gmail.com",{"facility":146,"status":31,"city":147,"state":24,"zip":148,"country":149,"countryCode":150,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"ICM La Pitie Salpetriere","Paris","75013","France","FR",{"type":38,"coordinates":152},[153,154],2.3488,48.85341,{"lat":154,"lon":153},[157],{"name":158,"role":46,"phone":159,"phoneExt":24,"email":160},"Fanny Mochel","+ 33 (0)1 57 27 41 23","fanny.mochel@icm-institute.org",{"facility":162,"status":31,"city":163,"state":24,"zip":164,"country":165,"countryCode":166,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"Klinik und Poliklinik für Neurologie-Leipzig","Leipzig","04103","Germany","DE",{"type":38,"coordinates":168},[169,170],12.37129,51.33962,{"lat":170,"lon":169},[173],{"name":174,"role":46,"phone":175,"phoneExt":24,"email":176},"Caroline Bergner","+49 341 97 11747","Caroline.Bergner@medizin.uni-leipzig.de",{"facility":178,"status":31,"city":179,"state":24,"zip":180,"country":181,"countryCode":182,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Sir Ganga Ram Hospital","New Delhi","110060","India","IN",{"type":38,"coordinates":184},[185,186],77.2148,28.62137,{"lat":186,"lon":185},[189],{"name":190,"role":46,"phone":191,"phoneExt":24,"email":192},"C.S Agrawal","+91 11 4225 1099","csyvaa@gmail.com",{"facility":194,"status":31,"city":195,"state":24,"zip":196,"country":197,"countryCode":198,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"Hospital 12 de Octubre","Madrid","28041","Spain","ES",{"type":38,"coordinates":200},[201,202],-3.70256,40.4165,{"lat":202,"lon":201},[205],{"name":206,"role":46,"phone":207,"phoneExt":24,"email":208},"Montserrat Morales","630 742 050","montserrat.morales@salud.madrid.org",{"facility":210,"status":31,"city":211,"state":24,"zip":212,"country":213,"countryCode":214,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"National Hospital for Neurology and Neurosurgery","London","WC1N 3AX","United Kingdom","UK",{"type":38,"coordinates":216},[217,218],-0.12574,51.50853,{"lat":218,"lon":217},[221],{"name":222,"role":46,"phone":223,"phoneExt":24,"email":224},"Robin Lachman","+442034484778","r.lachmann@nhs.net",{"type":226,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100502254","phase-3-a-clinical-study-to-assess-the-efficacy-and-safety-of-leriglitazone-in-adult-male-subjects-with-cerebral-adrenoleukodystrophy-100502254",false,"NCT05819866","A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy","CALYX","Key Inclusion Criteria:\n\n* Subject is male and aged ≥18 years.\n* Subject has progressive cALD, defined as GdE+ brain lesions.\n* Subjects for whom HSCT is not recommended by the investigator or subject is not willing to undergo HSCT.\n* Subject has a Loes score ≥0.5 and ≤12 at Screening.\n* Subject does not have major functional disability in the Major Functional Disabilities-Neurological Function Score (MFD-NFS), except for \"wheelchair bound\" or \"total incontinence\", which will be allowed as these are considered expected symptoms of AMN in the time course of the disease\n* Subject does not have major cognitive impairment which would impair his ability to take part in the study as determined by the investigator at screening.\n\nKey Exclusion Criteria:\n\n* Subject who had previous bone marrow transplantation (HSCT) or treatment with ex-vivo gene therapy (eli-Cel).\n* Subject has known type 1 or type 2 diabetes.\n* Subject has known hypersensitivity or intolerance to pioglitazone or any other thiazolidinedione.\n* Subject is taking or has taken honokiol, pioglitazone, or other thiazolidinediones within 3 months prior to Screening.\n* Subject with current participation in another interventional clinical study or within 1 month prior to Screening.\n* Subject with other medical, neuropsychiatric or social conditions that, in the opinion of the investigator, are likely to adversely affect the risk-benefit of study participation, interfere with study compliance, or confound the study results.","MALE","18 Years",{"count":237,"type":238},40,"ESTIMATED","INTERVENTIONAL",[241],"PHASE3","A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.",[244],"Cerebral Adrenoleukodystrophy (cALD)","2025-11-14",{"date":247,"type":248},"2025-11-17","ACTUAL",{"date":250,"type":248},"2023-07-12",{"date":252,"type":238},"2027-05",{"name":5,"class":6},13]